Compare Krispy Kreme Inc (DNUT) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Krispy Kreme Inc vs Heron Therapeutics Inc — how do they compare? Krispy Kreme Inc trades at $3.11 (market cap $544.79M), while Heron Therapeutics Inc trades at $0.32 (market cap $63.41M). The key difference: Krispy Kreme Inc is far larger — about 8.6× Heron Therapeutics Inc's market cap, and Krispy Kreme Inc pays a 3.47% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| DNUT | HRTX | |
|---|---|---|
Market Cap | $544.79M | $63.41M |
Sector | Consumer Staples | Health |
52-Week High | $4.70 | $1.49 |
52-Week Low | $2.92 | $0.33 |
Enterprise Value | $1.79B | $161.31M |
Dividend Yield | 3.47% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Krispy Kreme (DNUT) trades at $3.34, up 3.41% today, with a bullish technical signal from oscillators and mixed earnings history. The company reported a net loss of -$515.77M in 2025 but shows margin improvement and a capital-light refranchising strategy. Recent news highlights a turnaround focus, with the CEO affirming progress on profitability and leverage reduction.
Outlook hinges on execution of the turnaround plan; opportunities include international expansion and cost controls, but risks persist from high debt and competitive pressures. Analysts are cautiously optimistic with a 50% buy rating, though negative profitability metrics warrant monitoring.
Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.
HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Krispy Kreme Inc
Krispy Kreme Inc is a sweet treat brands company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in- your-mouth experience. It operates in 30 countries through its network of fresh Doughnut Shops, partnerships with retailers, and a growing ecommerce and delivery business. The company conducts its business through the following three reported segments namely U.S. and Canada, includes all operations in the U.S. and Canada, Insomnia Cookies shops, and the Branded Sweet Treat Line
Read more on DNUT →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
